Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
Ibotta disclosed its financial results for the second quarter on August 13, 2024, marking its first report since its initial public offering (IPO), revealing a net loss of $34.0 million, which constitutes 39% of its revenue for the period. The company reported a 19% decline in direct-to-consumer redemptions on a year-over-year basis, accompanied by a 7% reduction in the number of direct-to-consumer redeemers. Furthermore, the total number of redemptions per redeemer exhibited a notable year-over-year decrease of 39%. Additionally, the revenue generated per redemption exhibited a year-over-year decline over 19%.
Ticker Symbol | Company Name | Join Deadline | Join |
---|---|---|---|
APLT | Applied Therapeutics, Inc. | February 18, 2025 | Join |
BIOA | BioAge Labs, Inc. | March 10, 2025 | Join |
PCRX | Pacira BioSciences, Inc. | March 14, 2025 | Join |
NVO | Novo Nordisk A/S | March 25, 2025 | Join |
GO | Grocery Outlet Holding Corp. | March 31, 2025 | Join |
NEM | Newmont Corporation | April 01, 2025 | Join |
GSK | GSK plc | April 07, 2025 | Join |
NTLA | Intellia Therapeutics, Inc. | April 14, 2025 | Join |
MRK | Merck & Co., Inc. | April 14, 2025 | Join |